What is orthopedic cell therapy
We use autologous mesenchymal stromal cells (MSC) — adult progenitor cells from the patient's own tissue. They have three key properties the method is built upon:
Chondrocyte differentiation
In the joint environment MSCs can become chondrocytes and synthesize cartilage matrix (type II collagen, proteoglycans).
Paracrine effect
MSCs secrete hundreds of biologically active molecules (exosomes, cytokines, growth factors), stimulating the patient's own cells to regenerate. Often more important than direct differentiation.
Immunomodulation
MSCs suppress pathological inflammation (IL-10, TGF-β, PGE2) without causing immunosuppression. Effective when an inflammatory component is present in arthrosis.
Important note
MIBRAR® does NOT use embryonic, fetal or induced pluripotent (iPSC) cells. Only the patient's own cells, no genetic manipulation. This is a mandatory EU regulatory requirement.
Lipogems® vs SVF vs BMAC
Lipogems® Ortho
Mechanically processed adipose tissue. Stroma and pericytes are preserved. Harvest — mini-liposuction of 20–60 mL from the abdomen/thigh under local anesthesia. EU gold standard: legal by design — no ATMP license required.
SVF (Stromal Vascular Fraction)
Stromal vascular fraction of adipose tissue. Higher MSC concentration but requires enzymatic processing (collagenase). In Europe, restricted use; MIBRAR® uses only on strict indications.
BMAC (Bone Marrow Aspirate Concentrate)
Bone marrow concentrate from an iliac crest puncture. Contains MSC + hematopoietic cells + growth factors. Optimal for bone defects, osteonecrosis, large chondral lesions.
In MIBRAR® cell therapy is usually combined with CGF/PRP in one visit — for a synergistic regenerative effect.
When cell therapy is indicated
Severe arthrosis (stage II–III)
Knee, hip, shoulder, ankle. When PRP/CGF is no longer sufficient but endoprosthesis is still premature. Lipogems® + CGF is a standard protocol.
Large chondral defects
Osteochondral lesions of the knee and ankle. Combined with microfracture, AMIC or matrix-induced chondrocyte implantation.
Failed Back Surgery Syndrome
Chronic pain after spine surgery. SVF/BMAC into facet joints and the epidural space under fluoroscopic control.
Osteonecrosis
Avascular necrosis of the femoral head, humeral head, knee at early stages. BMAC into the necrosis zone — slowing or arresting head collapse.
Large rotator cuff tears
Degenerative tears with poor blood supply. Cell therapy improves biological healing conditions — before or after surgery.
Degenerative disc disease
Significant disc height loss, Modic changes. Intradiscal BMAC — experimental but promising under strict protocols.
Legal status in the EU
MIBRAR® uses only products compliant with European regulation (Directive 1394/2007, Regulation 2017/745):
Non-ATMP products
Lipogems®, BMAC — minimally manipulated autologous tissues used within a single surgical intervention. No ATMP license required.
No genetic modifications
Cells are not lab-expanded, not genetically modified. This is the critical distinction between MIBRAR® and experimental "stem cell clinics" in some countries.
Clinic in Germany
MIBRAR® headquarters is in Munich. All activity under BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte) and German medical regulation.
How the procedure works
1. Tissue harvest
For Lipogems® — mini-liposuction of 20–60 mL under local anesthesia (15–20 min). For BMAC — iliac crest puncture (10 min).
2. In-clinic processing
Lipogems® — mechanical processing in a closed system (15–20 min). BMAC — centrifugation. All done in one operating room, no transport.
3. Injection under navigation
Injection under ultrasound + Sono-Control Arm + Cyber-Navi-Hand into the damage zone. Local anesthesia. 15–30 min.
4. Observation and home
1–2 hours in clinic, then home. Mild tenderness at the harvest site for 3–5 days. Moderate activity from day one, sport — in 4–6 weeks.
Find out if cell therapy is right for you
Upload MRI and description — receive a free preliminary doctor's opinion.
Submit a requestFrequently asked questions
Autologous mesenchymal cells from the patient's own fat or bone marrow. Embryonic cells are NOT used in MIBRAR®.
Yes. We use Lipogems® (mechanical processing, no enzymes) — EU-compliant.
Lipogems® — mechanically processed fat. SVF — concentrated cellular product from fat. BMAC — bone marrow concentrate. Chosen by indication.
Local anesthesia. Harvest is a mini-liposuction or iliac crest puncture. Minimal discomfort.
First improvement — 2–4 weeks. Peak — 3–6 months. Follow-up MRI at 6 and 12 months.
